Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis
Amyloid ( IF 5.5 ) Pub Date : 2023-05-22 , DOI: 10.1080/13506129.2023.2169124 Sriram Ravichandran 1 , Andrew Hall 2 , Matthew Jenner 3 , Mamta Garg 4 , Bhuvan Kishore 5 , Helen Lachmann 1 , Julian Gillmore 1 , Alexandra Pitchford 2 , Jamie B Oughton 2 , Shameem Mahmood 1 , Sajitha Sachchithantham 1 , Philip Hawkins 1 , Sarah Brown 2 , Ashutosh Wechalekar 1
Amyloid ( IF 5.5 ) Pub Date : 2023-05-22 , DOI: 10.1080/13506129.2023.2169124 Sriram Ravichandran 1 , Andrew Hall 2 , Matthew Jenner 3 , Mamta Garg 4 , Bhuvan Kishore 5 , Helen Lachmann 1 , Julian Gillmore 1 , Alexandra Pitchford 2 , Jamie B Oughton 2 , Shameem Mahmood 1 , Sajitha Sachchithantham 1 , Philip Hawkins 1 , Sarah Brown 2 , Ashutosh Wechalekar 1
Affiliation
Proteasome inhibitors are the backbone of AL amyloidosis treatment – bortezomib being most widely used. Carfilzomib is a proteasome inhibitor licenced to treat multiple myeloma; autonomic and perip...
中文翻译：
卡非佐米联合沙利度胺和地塞米松治疗复发/难治性全身性免疫球蛋白轻链淀粉样变性患者的 1b 期剂量递增研究
蛋白酶体抑制剂是 AL 淀粉样变性治疗的支柱——硼替佐米应用最广泛。卡非佐米是一种蛋白酶体抑制剂，被许可用于治疗多发性骨髓瘤；自主性和周边性...
更新日期：2023-05-22
中文翻译：
卡非佐米联合沙利度胺和地塞米松治疗复发/难治性全身性免疫球蛋白轻链淀粉样变性患者的 1b 期剂量递增研究
蛋白酶体抑制剂是 AL 淀粉样变性治疗的支柱——硼替佐米应用最广泛。卡非佐米是一种蛋白酶体抑制剂，被许可用于治疗多发性骨髓瘤；自主性和周边性...
京公网安备 11010802027423号